CBAY
Closed
Cymabay Therapeu
32.48
+0.01 (+0.03%)
Last Update: 25 Mar 2024 16:30:00
Yesterday: 32.47
Day's Range: 32.48 - 32.48
Send
sign up or login to leave a comment!
When Written:
8.72
Cymabay Therapeutics is a biopharmaceutical company that focuses on developing therapies for liver and other chronic diseases. The company's lead product candidate, seladelpar, is a selective peroxisome proliferator-activated receptor delta agonist that is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Seladelpar has shown promising results in clinical trials and has received Fast Track designation from the US FDA for the treatment of PBC. Cymabay Therapeutics is also developing other product candidates for the treatment of liver and other chronic diseases, including a preclinical program for the treatment of fibrotic diseases. The company is headquartered in Newark, California, USA.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








